Loading organizations...
§ Public · Philadelphia, PA, USA
Biotechnology company developing allogeneic cell therapies from iPSCs for oncology, focused on off-the-shelf NK and T cells.
Century Therapeutics is a Philadelphia, Pennsylvania-based biotechnology company that develops allogeneic cell therapies derived from induced pluripotent stem cells for the treatment of solid tumors and hematological malignancies. The publicly traded enterprise operates with a dedicated team of 78 employees and currently maintains an estimated enterprise value of $11.8 million. Prior to its public market debut, the organization secured a $250 million Series A financing round before raising an additional $243 million through its 2021 initial public offering. The firm's clinical advancement and manufacturing platform is supported by strategic partnerships and venture investments from prominent entities including Versant Ventures, Fujifilm Cellular Dynamics, and Leaps by Bayer. To guide its ongoing oncology research, the company recently appointed Brent Pfeiffenberger as chief executive officer. Century Therapeutics was founded in 2018 by Lalo Flores alongside scientific co-founders Marcela Maus and Hiro Nakauchi.
Century Therapeutics has raised $605.0M across 4 funding rounds.
Century Therapeutics has raised $605.0M in total across 4 funding rounds.
Century Therapeutics has raised $605.0M in total across 4 funding rounds.
Century Therapeutics's investors include TCGX, Commodore Capital, Deep Track Capital, JDRF T1D Fund, RA Capital Management, RTW Investments, Venrock, Adage Capital Management, Bain Capital Life Sciences, Octagon Capital, Superstring Capital, Boxer Capital.
Century Therapeutics has raised $605.0M across 4 funding rounds. Most recently, it raised $135.0M Other Equity in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2026 | $135M Venture Round | TCGX | Commodore Capital, Deep Track Capital, JDRF T1D Fund, RA Capital Management, RTW Investments, Venrock | Announced |
| Apr 12, 2024 | $60M Venture Round | Adage Capital Management, Bain Capital Life Sciences, Octagon Capital, Superstring Capital | Boxer Capital, Casdin Capital, Dafna Capital, Venrock | Announced |
| Mar 1, 2021 | $160M Series C | Casdin Capital | Versant Ventures, Qatar Investment Authority, Marshall Wace, Octagon Capital, OrbiMed, RA Capital Management, Avidity Partners, Federated Kaufmann Fund, Fidelity Management & Research Company, Leaps BY Bayer, Logos Capital | Announced |
| Jun 1, 2019 | $250M Series A | — | Versant Ventures, Toshikazu BAN, Juergen Eckhardt | Announced |
Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies, primarily natural killer (NK) and T cells, to treat cancer and autoimmune diseases.[1][2][4] These off-the-shelf therapies target unmet needs in oncology, such as relapsed or refractory hematologic and solid tumors, by overcoming limitations of autologous CAR-T treatments like patient-specific manufacturing delays, high costs, and risks of graft-versus-host disease.[3][4][6] The company serves patients with hard-to-treat cancers and autoimmune conditions, leveraging its proprietary iPSC platform for scalable, accessible products that offer superior efficacy and durability.[2][3][4] Growth momentum includes a transformative $250 million Series A in 2018, ongoing clinical advancements as of April 2025, strategic partnerships, and recent board appointments in December 2025.[1][4]
Founded in 2018, Century Therapeutics emerged from breakthroughs in iPSC technology to pioneer allogeneic cell therapies, securing a pivotal $250 million Series A round that fueled platform development and positioned it as a leader in the space.[1] Key scientific leaders include Dr. Farid (drug development and immunology expertise), Dr. Cowan (scientific discovery and pipeline advancement), and Dr. Levitsky (disease mechanisms and therapeutic development), who drive translation from research to clinical applications.[3] The idea stemmed from addressing autologous therapy flaws—such as manufacturing delays and dysfunctional patient cells—evolving into a focus on unlimited self-renewing iPSCs for off-the-shelf NK and T cell products.[1][4][6] Early traction came from attracting top talent and partnerships, humanizing its mission through values like integrity, passion, science, and courage.[5]
Century rides the wave of next-generation cell therapy evolution, shifting from autologous CAR-T's proven but limited success in blood cancers to allogeneic iPSC-derived options for broader cancers and autoimmune diseases.[4][6] Timing aligns with surging demand for scalable immunotherapies amid rising cancer prevalence and autoimmune challenges, fueled by manufacturing innovations reducing costs and delays.[1][2][3] Market forces like strategic pharma partnerships and clinical momentum favor Century, influencing the ecosystem by pioneering accessible treatments, engaging patient communities, and redefining immuno-oncology paradigms.[3][4][5]
Century is poised to advance its pipeline through clinical trials, leveraging recent leadership additions like Dr. Han Lee and Dr. Martin Murphy to accelerate autoimmune and oncology programs.[4] Trends in scalable iPSC manufacturing and combo therapies will shape its path, potentially expanding influence via approvals for solid tumors and autoimmune indications. As a frontrunner in allogeneic cell therapies, Century could transform patient access, building on its 2018 funding launch to deliver curative impacts in unmet areas.[1][2][4]